Market Intelligence, Clinical Progress, and High-Purity Reagents for ER Stress Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATF6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (bZIP Domain) | ATF6 bZIP Domain Recombinant Protein Sequence Verified, High Purity (>95%), E. coli Expressed. For DNA-binding assays. |
View ATF6 Products |
| Antigen (Lumenal Domain) | ATF6 ER Lumenal Domain-Fc Fusion HEK293 Expressed (Native Glycosylation), Endotoxin <1EU/ug. For small molecule screening. |
View ATF6 Products |
| Cytosolic Domain (Mutant) | ATF6 Cytosolic Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for SPR/BLI and PROTAC ternary complex studies. |
View ATF6 Products |
| Gene Delivery | ATF6 ORF Lentivirus Full-length Type II membrane protein for stable cell line construction. Sequence Verified. |
View ATF6 Products |
| Benchmark Antibody | Anti-ATF6 (Research Grade) Recombinant positive control for western blot and intracellular target engagement. |
View ATF6 Products |
| Validator | ATF6 siRNA Set For knockdown verification and UPR pathway specificity control. |
View ATF6 Products |
| Related Target: IRE1 | IRE1 (ERN1) Parallel UPR sensor. Essential for cross-pathway selectivity assays. |
View ERN1 Products |
| Related Target: PERK | PERK (EIF2AK3) Alternative UPR branch. Required for off-target liability screening. |
View EIF2AK3 Products |
| Related Target: BiP | BiP (HSPA5/GRP78) ATF6 regulatory chaperone. For mechanism-of-action studies. |
View HSPA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Direct Binder Screening (Small Molecules/PROTACs) | High-purity E. coli/Baculovirus expressed cytosolic domains (>95%) for SPR/TR-FRET. Mutant constructs available. |
| Cross-UPR Selectivity (vs IRE1/PERK pathways) | Purified ATF6 bZIP domain with homolog-specific epitopes preserved. Parallel IRE1/PERK proteins for counter-screening. |
| ER Membrane Context & Golgi Trafficking | Lentivirus particles for stable cell lines with Type II membrane topology. Supports S1P/S2P cleavage studies and trafficking assays. |
| Intracellular Pathway Validation & Reporter Assays | Lentiviral vectors for native-conformation reporter construction. siRNA included for target-specific signal verification. |
| Lack of Reliable Controls & Target Engagement Specificity | Sequence-verified recombinant antibodies and siRNA sets for robust baseline and genetic knockdown controls. |
Live ATF6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ATF6-targeted therapeutics is intensifying around two opposing paradigms: activation for protein misfolding diseases (neurodegeneration, retinal dystrophies) versus inhibition for cancer (where ATF6 drives pro-survival UPR). As first-generation small molecules (AA147-class activators, Ceapin-class inhibitors) advance through preclinical validation, the next wave of R&D is targeting isoform-selective modulation (ATF6α vs ATF6β) and organelle-specific delivery to minimize off-target UPR activation. Concurrently, major players are shifting focus from broad ER stress inhibitors to highly selective small molecule modulators and targeted protein degraders (PROTACs). The role of UPR in tumor survival and neurodegeneration is becoming clearer, requiring rigorous biochemical and cell-based assay platforms to prevent cross-reactivity with IRE1 and PERK.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Academic consortia (UCSF, Harvard), Calico, Scripps Research, Disarm Therapeutics | ALS, Alzheimer's, Retinitis Pigmentosa, Ischemia | Lumenal Domain Binding (Need HEK293-expressed native glycosylated protein) |
| Small Molecule Inhibitors | UCSF (Ceapins), Eisai, Academic/Biotech Consortiums | Solid Tumors, Multiple Myeloma, Diabetic Retinopathy | Golgi Trafficking Blockade Assay (Need full-length Lentivirus stable lines) |
| PROTAC Degraders | Academic groups, Early Stage Biotech | Refractory Cancers, Cancer | Cleavage State Specificity & Ternary Complex Validation (Need bZIP domain purity >95% for ubiquitination assays) |
| Gene Therapy / siRNA | Regenxbio, Spark Therapeutics, Preclinical Pharms | Inherited Retinal Diseases, Rare Genetic Diseases | Overexpression/Knockdown Validation (Need ORF Lentivirus and target antigens) |